tiprankstipranks
OncoSec Medical (ONCSQ)
OTHER OTC:ONCSQ
Holding ONCSQ?
Track your performance easily

OncoSec Medical (ONCSQ) Stock Price & Analysis

487 Followers

ONCSQ Stock Chart & Stats


Financials

Annual

Ownership Overview

2.12%97.88%
Insiders
Mutual Funds
2.12% Other Institutional Investors
97.88% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

ONCSQ FAQ

What was OncoSec Medical’s price range in the past 12 months?
Currently, no data Available
What is OncoSec Medical’s market cap?
Currently, no data Available
When is OncoSec Medical’s upcoming earnings report date?
OncoSec Medical’s upcoming earnings report date is Mar 12, 2025 which is in 110 days.
    How were OncoSec Medical’s earnings last quarter?
    Currently, no data Available
    Is OncoSec Medical overvalued?
    According to Wall Street analysts OncoSec Medical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does OncoSec Medical pay dividends?
      OncoSec Medical does not currently pay dividends.
      What is OncoSec Medical’s EPS estimate?
      OncoSec Medical’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does OncoSec Medical have?
      OncoSec Medical has 5,962,652 shares outstanding.
        What happened to OncoSec Medical’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of OncoSec Medical?
        Currently, no hedge funds are holding shares in ONCSQ
        ---

        OncoSec Medical Stock Smart Score

        10
        Unlock Smart Score
        1
        2
        3
        4
        5
        6
        7
        8
        9
        10

        Company Description

        OncoSec Medical

        OncoSec Medical, Inc. is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered inPennington, NJ.
        ---
        Similar Stocks
        Company
        Price & Change
        Follow
        Inovio Pharmaceuticals
        Oncternal Therapeutics
        Cellectar Biosciences
        Immutep
        Popular Stocks
        ---
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis